MLABHIGH SIGNALFINANCIAL10-K

MLAB achieved a dramatic turnaround from -$272M operating loss to $16M operating profit while significantly increasing debt levels by 210%.

The company has successfully executed a major operational turnaround, moving from substantial losses to profitability, which suggests effective cost management and business restructuring. However, the massive increase in current liabilities (270%) and total debt (210%) indicates significant financial restructuring or new obligations that require close monitoring for liquidity and leverage concerns.

Comparing 2025-05-28 vs 2024-06-28View on EDGAR →
FINANCIAL ANALYSIS

MLAB demonstrated a remarkable financial turnaround with operating income swinging from -$272M to +$16M and net losses narrowing dramatically from -$254M to just -$2M, while revenue grew modestly by 11% and gross profit increased 13%. The company significantly increased its debt burden with total debt rising 210% to $71M and current liabilities surging 270% to $164M, though inventory decreased 22% suggesting improved working capital management. This represents a company emerging from a loss-making period into profitability but with substantially higher leverage that investors must monitor carefully.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+270%
$44.3M$164.0M

Current liabilities surged 270% — significant near-term obligations; verify ability to meet short-term debt.

Total Debt
Balance Sheet
+209.8%
$23.0M$71.3M

Debt increased 209.8% — substantial leverage increase; assess whether deployed for growth or covering losses.

Operating Income
P&L
+106%
-$272.1M$16.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+99.2%
-$254.2M-$2.0M

Net income grew 99.2% — bottom-line growth signals improving overall business health.

Share Buybacks
Cash Flow
-77.6%
$98K$22K

Buyback activity reduced 77.6% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
+65.5%
$2.6M$4.2M

Capital expenditure jumped 65.5% — major investment cycle underway; assess returns on deployment.

Inventory
Balance Sheet
-22.4%
$32.7M$25.4M

Inventory reduced 22.4% — lean inventory management or demand outpacing supply.

Gross Profit
P&L
+13.2%
$133.3M$150.9M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+11.1%
$34.2M$38.0M

Revenue growing 11.1% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2025-05-28
PRIOR — 2024-06-28
ADDED
Gross profit as presented is consistent with GAAP measurement principles and our CODM's review of segment information.
Includes GKE results beginning upon acquisition in fiscal year 2024.
Certain depreciation expense classified reflected in Corporate and Other in fiscal years 2024 and 2023 has been recast to conform to current year presentation.
Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
Revenues of $9,289 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2024 and represent sales made beginning from the acquisition date.
+7 more — sign up free →
REMOVED
Acquired goodwill of $48,850, all of which is allocated to the Sterilization Disinfection Control division, represents the value expected to arise from the benefits of expanded market opportunities, particularly in the healthcare industry, as well as expected synergies and GKE's assembled workforce, none of which qualify as amortizable intangible assets.
taxes with respect to GILTI; the goodwill is not expected to be deductible for foreign tax purposes.
Includes $2,353 of fixed asset step up, which will be amortized based on the underlying assets' expected lives.
During the period from October 16, 2023 to March 31, 2024, $365 of property, plant and equipment step up was recorded to depreciation expense.
Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →